Jerome De Vente

Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice.

M.M. McGrane, Jerome De Vente, Jeong‐Ho Yun et al. · Journal of Biological Chemistry · 1988 · 241 citations · Full text

Fertility, Mammalian Physiology, Genetics +18

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

David A. Margolis, Cynthia Brinson, Graham Smith et al. · The Lancet Infectious Diseases · 2015 · 198 citations

Phase 2B, Human Retrovirus, Pharmacology +10

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Protease Inhibitors, Treatment And Prevention, Pharmacology +9

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Joseph J. Eron, Chloe Orkin, Douglas Cunningham et al. · Antiviral Research · 2019 · 36 citations · Full text

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

Anthony Mills, Gary Richmond, Cheryl Newman et al. · AIDS · 2021 · 34 citations · Full text